Skip to main content

Table 5 Pooled estimates for CRT reduction from baseline for PDT versus anti-VEGF

From: Photodynamic therapy versus anti-vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: A meta-analysis

Outcome of interest Studies (n) WMD (95 % CI) Test for Overall Effect Study Heterogeneity
χ2 p I2
CRT Reduction (3mo)
Design       
 All trials 5 18.69 (−0.83, 38.20) Z =1.88, P =0.061 2.36 0.670 0.00 %
 Retro 3 22.75 (−0.96, 44.54) Z =1.05, P =0.141 1.56 0.459 0.00 %
 RCT 2 2.24 (−41.62, 46.09) Z =0.10, P =0.920 0.13 0.719 0.00 %
Type of OCT       
 TD-OCT 3 10.47 (−30.90, 51.85) Z =0.50, P =0.620 1.29 0.526 0.00 %
 SD-OCT 2 21.03(−1.09, 43.17) Z =1.86, P =0.062 0.88 0.348 0.00 %
CRT Reduction (6mo)
Design
 All trials 4 44.94 (16.44, 73.44) Z =3.09, P =0.002 4.30 0.231 30.3 %
 Retro 2 36.87 (14.58, 59.16) Z =3.24, P =0.001 0.65 0.421 0.00 %
 RCT 2 66.62 (3.42, 129.81) Z =2.07, P =0.039 2.05 0.152 51.3 %
Type of OCT       
 TD-OCT 2 22.15 (2.98, 67.30) Z =2.06, P =0.038 0.17 0.678 0.00 %
 SD-OCT 2 62.13 (8.19, 116.07) Z =2.26, P =0.024 3.08 0.079 67.5 %
CRT Reduction (12mo)
Design
 All trials 3 13.91(−42.14, 69.97) Z =0.49, P =0.627 8.48 0.014 76.4 %
 Retro 2 36.03 (−13.52, 85.58) Z =1.43, P =0.154 2.48 0.115 59.6 %
 RCT 1 13.91 (−42.14, 69.97) Z =1.00, P =0.315 - -  
Type of OCT       
 TD-OCT 1 1.35 (−60.65, 63.35) Z =0.04, P =0.966 - - -
 SD-OCT 2 16.70 (−65.61, 99.00) Z =0.40, P =0.691 6.92 0.009 85.6 %
  1. CRT central retinal thickness; PDT photodynamic therapy; VEGF vascular endothelial growth factor; WMD weighted mean differences; CI confidence interval; Retro retrospective comparative study; RCT prospective randomized controlled trial; OCT optical coherence tomography; TD-OCT time-domain optical coherence tomography; SD-OCT spectral-domain optical coherence tomography